Jiyeon Kim

Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer

Immune checkpoint inhibitors are now standard care for small-cell lung cancer (SCLC); however, a profound prognostic disparity persists between limited-stage (LS) and extensive-stage (ES) disease. Although clinical staging defines tumor spread, the specific molecular characterist...